Hematologic Oncology | Specialty

Dr. Rizvi on Treatment Considerations in Stage III/IV Hodgkin Lymphoma

February 11th 2020

Syed Rizvi, MD, an assistant professor in the Department of Internal Medicine at UT Southwestern Medical Center, discusses treatment considerations in stage III/IV Hodgkin lymphoma.

Dr. Vusirikala on the Role of Transplant in ALL

February 11th 2020

Madhuri Vusirikala, MD, discusses the role of transplant in acute lymphoblastic leukemia.

Dr. Kaplan on the Use of PI3K Inhibitors in Follicular Lymphoma

February 8th 2020

Lawrence D. Kaplan, MD, clinical professor of medicine, director, Adult Lymphoma Program, Division of Hematology-Oncology, University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the use of PI3K inhibitors in follicular lymphoma.

Dr. DiNardo on Rationale to Combine Enasidenib and Azacitidine in AML

February 7th 2020

Courtney DiNardo, MD, MSCE, discusses the rationale to combine enasidenib (Idhifa) with azacitidine in acute myeloid leukemia.

Dr. Brammer on the Role of Stem Cell Transplant in ALL

February 7th 2020

Jonathan E. Brammer, MD, discusses the role of stem cell transplant in acute lymphoblastic leukemia.

Dr. Mims on Waiting for Molecular Tests Before Starting Therapy in AML

February 6th 2020

Alice S. Mims, MD, discusses her recommendations regarding holding therapy until molecular test results are received for symptomatic patients with acute myeloid leukemia.

Dr. Awan on the Role of Chemotherapy in CLL

February 5th 2020

Farrukh Awan, MD, discusses the role of chemotherapy in the treatment of patients with chronic lymphocytic leukemia (CLL).

Dr. Olin on FLT3 Inhibitor Research in AML

February 5th 2020

Rebecca L. Olin, MD, MSCE, discusses research surrounding FLT3 inhibitors as a treatment for patients with acute myeloid leukemia.

Inaugural HCT Guideline Focuses on Patient Selection, GVHD Treatment

February 4th 2020

In response to a rise in hematopoietic cell transplantation, the National Comprehensive Cancer Network has published its first guideline for the specialized intervention, which is performed approximately 22,000 times a year in the United States in patients with hematological cancers and other diseases.

Dr. Patel on Delaying Treatment for Elderly Patients With Newly Diagnosed AML

February 4th 2020

Prapti Patel, MD, discusses delaying treatment until after genetic testing in elderly patients with newly diagnosed acute myeloid leukemia.

Experts Share What They're Going to Work on Improving in Practice This Year

February 1st 2020

OncLive interviewed experts at the State of the Science Summits™ in January 2020 on what they are going to work on improving in clinical practice this year.

Acute Lymphoblastic Leukemia: Future Directions in Therapy

February 1st 2020

MRD Testing in Hematologic Malignancies Other Than ALL

February 1st 2020

Future Directions for MRD Testing in ALL

February 1st 2020

Optimizing Use of Maintenance Therapy in ALL

February 1st 2020

MRD+ ALL: Evolving Role of BiTE Therapy

February 1st 2020

MRD's Impact on Subsequent Therapy Choice in ALL

February 1st 2020

Sensitivity of MRD Testing and Impact on Decisionmaking in ALL

February 1st 2020

Strategies to Assess Minimal Residual Disease

February 1st 2020

ALL: When and Who to Test for Minimal Residual Disease

February 1st 2020